Predictors of Type 2 Diabetes Remission and Relapse After Metabolic-Bariatric Surgery or Medical-Lifestyle Therapy in the ARMMS-T2D Study
Diabetes Care · 20.10.2026
DOI: 10.2337/dc26-1070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 20.10.2026. Verfasst von Donald C Simonson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital, Boston, MA. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE Metabolic-bariatric surgery (MBS) is effective in promoting remission of type 2 diabetes, but this outcome is not universally achieved. We identified baseline patient characteristics that predict diabetes remission and subsequent relapse after various MBS procedures versus intensive medical-lifestyle intervention. RESEARCH DESIGN AND METHODS Alliance of Randomized Trials of Medicine vs. Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) is a 14-year, multicenter study of health outcomes in 262 patients with type 2 diabetes (68% women, age 49.9 ± 8.3 years, BMI 36.4 ± 3.5 kg/m2, HbA1c 8.5 ± 1.5%) previously randomized to MBS (n = 166) or medical-lifestyle management (n = 96). Predictors of remission (defined as HbA1c <6.5% on no glucose-lowering medications) and relapse were determined using univariate time-to-event analyses of prespecified candidate predictors plus agnostic, multivariate least absolute shrinkage and selection operator. RESULTS Throughout a median of 11 years (maximum 14 years) of follow-up, 58% of participants randomized to MBS achieved diabetes remission versus 3% with medical-lifestyle management. Predictors of diabetes remission in univariate analyses included shorter diabetes duration, no insulin use, fewer glucose-lowering medication classes used, greater body weight, higher fasting C-peptide and insulin levels, and weight loss at 1 year (all P < 0.05). Diabetes remission predictors in multivariate analyses included baseline diabetes duration, insulin use, and weight change at 1 year (all P < 0.01). Diabetes relapse after initial remission in the MBS group was predicted by longer baseline diabetes duration and greater number of glucose-lowering medication classes used. CONCLUSIONS Baseline predictors of diabetes remission and subsequent relapse among participants randomized to one of three MBS procedures or a medical-lifestyle intervention should help inform personalized selection of diabetes treatment.
Autor:innen und Institutionen
- Brigham and Women's Hospital, Boston, MA.
- Harvard Medical School, Boston, MA.
- University of Washington Medical School, Seattle, WA.
- Pennington Biomedical Research Center, Baton Rouge, LA.
- Cleveland Clinic, Cleveland, OH.
- Duke University School of Medicine, Durham, NC.
ORCID-Profile: Donald C Simonson, Ali Aminian, John M Jakicic, Anita P Courcoulas, Mary Elizabeth Patti, John P Kirwan
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Simonson, D. C., Cummings, D. E., Schauer, P. R., Aminian, A., Hu, B., Arterburn, D. E., Jakicic, J. M., Kashyap, S. R., Vernon, A. H., Gourash, W. F., Courcoulas, A. P., Patti, M. E., & Kirwan, J. P. (2026). Predictors of Type 2 Diabetes Remission and Relapse After Metabolic-Bariatric Surgery or Medical-Lifestyle Therapy in the ARMMS-T2D Study. Diabetes Care. https://doi.org/10.2337/dc26-1070
Vancouver
Simonson DC, Cummings DE, Schauer PR, Aminian A, Hu B, Arterburn DE, et al. Predictors of Type 2 Diabetes Remission and Relapse After Metabolic-Bariatric Surgery or Medical-Lifestyle Therapy in the ARMMS-T2D Study. Diabetes Care. 2026. doi:10.2337/dc26-1070
BibTeX
@article{Simonson2026,
author = {Simonson, Donald C and Cummings, David E and Schauer, Philip R and Aminian, Ali and Hu, Bo and Arterburn, David E and Jakicic, John M and Kashyap, Sangeeta R and Vernon, Ashley H and Gourash, William F and Courcoulas, Anita P and Patti, Mary Elizabeth and Kirwan, John P},
title = {Predictors of Type 2 Diabetes Remission and Relapse After Metabolic-Bariatric Surgery or Medical-Lifestyle Therapy in the ARMMS-T2D Study},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dc26-1070}
}
EUVIMED